The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...